



3.4.6 Diagnosis and Treatment of Allergic Diseases



Publications: 59 | Q1: 36

COMPOSITION

Santiago Eugenio Quirce Gancedo.
Jefe de Servicio de Alergología. Hospital Universitario La Paz

- **Diana Betancor Pérez.** Médico Adjunto en Alergología. Hospital Universitario La Paz
- **María Teresa Caballero Molina.** Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz
- **María Luisa Caballero Soto.** Facultativo Especialista de Área en Inmunología. Hospital Universitario La Paz
- **Francisco Javier Contreras Porta.** Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz
- **Leticia de las Vecillas Sánchez.** Facultativo Especialista en Alergología. Hospital Universitario La Paz
- **Francisco Javier Domínguez Ortega.** Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz
- **Ana María del Carmen Fiandor Román.** Jefe de Sección de Alergología. Hospital Universitario La Paz

- **María del Mar Gandolfo Cano.** Jefe de Sección de Alergología Infantil. Hospital Universitario La Paz
- **Carmen Gómez Traseira.** Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz
- **Rosario González Mendiola.** Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz
- **Juan Alberto Luna Porta.** Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz
- **María Magdalena Lluch Bernal.** Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz
- **María Pedrosa Delgado.** Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz
- **Elsa Phillips Angles.** Facultativo Especialista de Área en Alergología Pediátrica. Hospital Universitario La Paz
- **Mónica Rodríguez Álvarez.** Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz
- **María Rosa Rodríguez Pérez.** Investigadora Titular. Jefe de Laboratorio. Hospital Universitario La Paz
- **Margarita Tomás Pérez.** Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz
- **Inés Torrado Español.** Facultativo Especialista de Área en Alergología. Hospital Universitario La Paz

STRATEGIC OBJETIVES

The group members are specialized in different areas of allergic pathology, which allows for clinical studies and basic research on the main allergic diseases (food allergy, asthma and rhinitis, urticaria/angioedema, and drug allergy).

The group's strategic research objectives are:

- Development of new techniques to improve the diagnosis of food allergies by determining the molecular sensitization profile
- Treatment of food allergy with oral desensitization protocols
- Study of hypersensitivity and bronchial inflammation in asthma, as well as the role of allergen exposure and comorbidities in this disease
- Study of the pathogenesis and treatment of eosinophilic diseases of the respiratory tract (eosinophilic bronchitis) and the digestive tract (eosinophilic esophagitis)
- Characterization of the different types of angioedema caused by bradykinin (hereditary and acquired) and improvements in its diagnosis and treatment
- Research on the epidemiology and mechanism of severe adverse reactions caused by immune hypersensitivity reactions to drugs

RESEARCH LINES

- Food allergy: molecular diagnosis (by allergenic components) and new diagnostic tests
- Epidemiology, pathophysiology, diagnosis and treatment of angioedema and urticaria
- Studies on bronchial hyperreactivity to direct and indirect agents and inflammation of the airways
- Eosinophilic diseases of the respiratory tract (eosinophilic bronchitis) and digestive system (eosinophilic esophagitis)
- Persistent and difficult-to-control asthma: a study on the influence of common and occupational allergens, comorbidities, and new therapies
- Aspirin-exacerbated respiratory disease (AERD): inflammatory biomarkers and diagnostic procedures
- Adverse immunological reactions to drugs: a study of the cellular and molecular mechanisms involved
- Identification and characterization of new environmental allergens and allergenicity modulating factors



1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

RESEARCH ACTIVITY

Doctoral Theses

- **Palao Ocharan PE.** Calidad de vida en angioedema hereditario por déficit de c1 inhibidor. estudio psicométrico del cuestionario genérico de calidad de vida relacionada con la salud (CVRS) SF-36 versión 2.0 (SF-36V2). Análisis de CVRS y estudio exploratorio de los determinantes de la CVRS mediante el cuestionario SF-36V2[dissertation]. Madrid: UAM: 2025(05/05/2025). Director: Caballero Molina MT.

Final Degree Theses

- **Salinas Lujan A.** Identificación y frecuencia de reconocimiento IgE mediado de los alérgenos del polen de Quercus ilex en pacientes sensibilizados[dissertation]. Alcalá de Henares: UAH: 2025(01/06/2025). Director: Rodríguez Pérez MR.
- **Cózar López R.** Identificación de globulinas en bellota de Quercus ilex como fuente de alergias[dissertation]. Córdoba: Universidad de Córdoba: 2025(01/05/2025). Director: Rodríguez Pérez MR

Publications

- **Agache I, Annesi-Maesano I, Cecchi L, Biagioni B, Chung F, D'Amato G, Damialis A, del Giacco S, Ortega JD, Galán C, Gilles S, Holgate S, Jeebhay M, Kazadzis S, Nadeau K, Papadopoulos NG, Quirce S, Sastre J, Traidl-Hoffmann C, Walusiak-Skorupa J, Zemelka-Wiacek M, Jutel M, Akdis CA.** EAACI Guidelines on environmental science for allergy and asthma-recommendations on the impact of indoor air pollutants on the risk of new-onset asthma and on asthma-related outcomes. *Allergy*. 2025; 80(3): 651-76. Article. IF: 11.3; Q1
- **Agache I, Salazar J, Rodriguez-Tanta Y, Saenz KKF, Hahtela T, Traidl-Hoffmann C, Damialis A, Vecillas L, Giovannini M, Nadeau KC, Pali-**

Schöll I, Palomares O, Renz H, Schwarze J, Pinto BS, Urrutia-Pereira M, Venter C, Vercelli D, Winders T, Sola-Arnau I, Alonso-Coello P, Canelo-Aybar C, Jutel M, Akdis CA. The impact of rhinovirus, syncytial respiratory virus and helminth infection on the risk of new-onset asthma and other allergic conditions-a systematic review for the EAACI guidelines on environmental science for allergic diseases and asthma. *Allergy*. 2025; 80(7): 1878-1898. Review. IF: 11.3; Q1

- **Almonacid C, Blanco M, Ferreira J, García G, Morete A, Quirce S, Soto-Campos G, Plaza V.** Key updates in the 2025 Spanish Asthma Guidelines (GEMA 5.5). *Open Respir Arch*. 2025; 7(3): 100453. Editorial Material. Not Indexed
- **Álvarez J, Parody N, Calzada D, Aranda T, Renshaw A, Serna S, Reichardt N, Beitia JM, González-de-Olano D, Domínguez-Ortega J, Carnes J.** Correlation between N-GLYCAN GNGNXF and the allergic immune response against juniperus ashei pollen. *Allergy*. 2025; 80(7): 1935-44. Article. IF: 11.3; Q1
- **Alves PB, Pablo-Torres C, Karavelia A, Fernández-Santamaría R, Giovannini M, Vecillas LD, Shamji M, Torres MJ.** Addressing the growing role of junior members in EAACI. *Allergy*. 2025; 80(9): 2682-5. Editorial Material. IF: 11.3; Q1
- **Arismendi E, Puente-Maestu L, Domingo C, Dávila I, Quirce S, Sánchez-Jareño M, Cea-Calvo L.** Emotions in patients with refractory or unexplained chronic cough: a multicenter, non-interventional study. *Ther Adv Respir Dis*. 2025; 19: 17534666251374900. Article. IF: 3.2; Q2
- **Betancor D, Rial MJ, Olaguibel JM, Del Pozo V, Puebla MJA, Arismendi E, Barroso B, Bobolea I, Cárdbaba B, Cañas JA, Domínguez-Ortega J, Crespo-Leshman A, Cruz MJ, de la Fuente AG, González-Barcalai EJ, Luna-Portac JA, Martínez-Rivera C, Mullol J, Muñoz X, Plaza V, Quirce S, Soto-Retes L, Valverde-**

Monge M, Sastre J. Stability of asthma biomarkers over a two-year period using three distinct classifications in the MEGA cohort. *Arch Bronconeumol*. 2025; 61(12): 794-6. Letter. IF: 8.7; D1

- **Betancourt A, Martínez-de-Ibarreta C, Calvo LA, Wirth E, Budria S, Antolín-Amérigo D, Colque-Bayona M, de la Rocha-ortiz I, Escalante-Carrero MD, Domínguez-Ortega J.** Asthma exacerbations, meteorological variables, and multipollutant concentrations: Uncovering short-term patterns through Association Rule Mining. *Environ Pollut*. 2025; 384: 127003. Review. IF: 7.2; Q1
- **Bianchini R, Escolar-Pena A, Pick V, Poli A, Adams R, Basilio J, Cari L, Chauhan J, Chivato T, Vecillas LD, Delgado-Dolset MI, Escribese MM, Grandits M, Bax HJ, Martin-Antoniano IA, Martin-Cruz L, Mayerhofer H, Michelucci A, Nocentini G, Osborn G, Pablo-Torres C, Palomares O, Pascal M, Radzikowska U, Rohr-Udilova N, Sokolowska M, Bergmann C, Jensen-Jarolim E, Karagiannis SN, Rebollido-Rios R, Izquierdo E.** Molecular signatures and functional pathways of human monocytes and macrophages in allergy: An EAACI allergooncology scoping review. *Allergy*. 2025; 80(10): 2710-25. Article. IF: 11.3; Q1
- **Blanco Aparicio M, Pérez de Llano L, Domínguez-Ortega J.** Severe asthma units in Spain: enhancing patient care and research in severe asthma. *Open Respir Arch*. 2025; 7(4): 100474. Article. Not Indexed
- **Caballero ML, Carpio-Hernández D, Parra P, Giraldo-Sánchez JC, Rodríguez-Álvarez M, Quirce S.** ISO 9001:2015 certification of the allergy laboratory. *J Invest Allerg Clin*. 2025; 35(2): 152-4. Letter. IF: 6.6; Q1
- **Calzada D, Bartra J, Serrano C, Riggioni S, Moran E, Maseli J, Silva D, Ramírez L, Pascal M, Cacheiro-Llaguno C, Valero A, Carnés J.** Comments to reply to differences in molecular

sensitization profiles between Spanish and Latin American mite-allergic patients. *J Invest Allerg Clin*. 2025; 35(5): 403-4. Letter. IF: 6.6; Q1

- **Calzada D, Parody N, Beitia JM, Domínguez-Ortega J, González-de-Olano D, Renshaw-Calderón A, Osuna C, Moya R, Carnés J.** Immunological parameters for assessing the in vitro safety and efficacy of allergoid mixtures for immunotherapy. *J Invest Allerg Clin*. 2025; 35(6): 441-51. Article. IF: 6.6; Q1
- **Castillo MA, Correa-Borít J, Laorden D, Adrianzen F, Villamanan E, Romero D, Quirce S, Domínguez-Ortega J.** Eosinophil and cationic protein levels in patients treated with dupilumab: a real-life study. *Open Respir Arch*. 2025; 7(3): 100444. Article. Not Indexed
- **Colque-Bayonai M, Domínguez-Ortega J, Tomás-Pérez M.** Cat and dog specific immunotherapy impact on quality of life and self-reported satisfaction in a real-world setting. *Eur Ann Allergy Clin Immunol*. 2025; 57(2): 91-5. Letter. IF: 2.5; Q3
- **Colque-Bayonai M, Laorden D, Romero D, Quirce S, Domínguez-Ortega J.** Anti-IL5/5R in the treatment of chronic eosinophilic pneumonia and severe asthma. *Eur Ann Allergy Clin Immunol*. 2025; 57(6): 286-8. Letter. IF: 2.5; Q3
- **Cremades-Jimeno L, López-Ramos M, Fernández-Santamaría R, de Pedro MA, Mahillo I, Rosales-Ariza C, Olaguibel JM, del Pozo V, Caballero ML, Luna-Porta JA, Quirce S, Barroso B, Betancor D, Valverde-Monge M, Sastre J, Baos S, Cárdbaba B.** Molecular study from the signaling pathways of four potential asthma triggers: AKT1, MAPK13, STAT1, and TLR4. *Int J Mol Sci*. 2025; 26(13): 6240. Article. IF: 5.6; Q1
- **Davila I, Carretero Gracia JA, Cebollero P, Izquierdo Alonso JL, Martínez-Moragon E, Morales-García C, Pérez Chica G, Quirce S, Soler-Cataluña JJ, Vinas M.** Efficient



1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

Management of Severe Asthma in the Clinic. *Open Respir Arch.* 2025; 7(3): 100456. Article. Not Indexed

- De Agrela-Méndes I, Correa-Borit J, López V, Ifrim M, Turiel C, De Las Vecillas L, Quirce S, Domínguez-Ortega J. Changes in the Nijmegen Questionnaire in severe asthma patients treated with dupilumab. *Rev Alerg Mex.* 2025; 72(4): 271-5. Article. Not Indexed
- de las Vecillas L, Sánchez-Jareño M, Lluch-Bernal M, Quirce S, Domínguez-Ortega J, López-carrasco V, Barranco P. Nasal challenge with ketorolac: utility and safety in clinical practice. *Eur Ann Allergy Clin Immunol.* 2025; 57(5): 236-8. Letter. IF: 2.5; Q3
- Delgado J, Cárdenas R, Gelis S, Domínguez-Ortega J. Allergen immunotherapy for the control of moderate to severe allergic asthma: an evidence-based conjoint analysis to define candidate patient profiles in Spain and Portugal. *Front Allergy.* 2025; 6: 1676399. Article. IF: 3.4; Q2
- Delgado Romero J, Soto-Retes L, Cisneros Serrano C, Blanco-Aparicio M, Ferrando Piqueres R, Díaz-Pérez D, López-Carrasco V, Merino-Bohorquez V, Domínguez-Ortega J. BioCart® opinion-based study on home administration support for biological therapies in patients with severe asthma. *Open Respir Arch.* 2025; 7(1): 100375. Article. Not Indexed
- Domínguez-Ortega J, Munoz Gall X, Delgado Romero J, Casas-Maldonado F, Blanco-Aparicio M. Degree of adherence to recommendations from the spanish consensus on the reduction of oral corticosteroid use in asthma patients: a questionnaire-based observational study. *Open Respir Arch.* 2025; 7(3): 100452. Article. Not Indexed
- Domínguez-Ortega J, Narváez-Fernández E, Ramos J, Cancelliere N, García-Criado J, Sánchez-Ocando H, Gallardo-Higueras A, Dávila I. Evaluation of real-world quality of asthma care according to the spanish consensus protocol: The AsmaNET Project (ESR-20-20897). *J Asthma Allergy.* 2025; 18(): 1119-1127. Article. IF: 3.3; Q2
- Domínguez-Ortega J, Virchow JC, Guillemínault L, Incalzi RA, Beyer AP, Ke XH,

Ding HL, Boggs R. Prevalence and burden of possible refractory chronic cough in four European countries. *ERJ Open Res.* 2025; 11(4): 8882024. Article. IF: 4.4; Q1

- Doyen V, Thirionet R, Miguères N, Vandenplas O, Sastre J, Valverde-Monge M, Grydeland TB, Munoz X, Romero-Mesones C, Suojalehto H, Suuronen K, van Kampen V, Eisenhawer C, Folletti I, Jacobsen IB, Walusiak-Skorupa J, Mason P, Preiser AM, Quirce S, Walters G, Riffart C, de Blay F, Svanes C. Phenotypic characteristics of occupational asthma caused by persulfate salts in hairdressers: a multicenter cohort study. *J Allergy Clin Immunol Pract.* 2025; 13(6): 1397-404. Article. IF: 7.2; D1
- Entrala A, Lluch-Bernal MM, Domínguez-Ortega J, Molero-Luis M, Sánchez GC, Quirce S, Rodríguez-Pérez R. Measurement of fecal calprotectin and zonulin as biomarkers in adults with fish-induced food protein-induced enterocolitis syndrome. *J Invest Allerg Clin.* 2025; 35(3): 2302. Editorial Material. IF: 6.6; Q1
- Escalera-Balsera A, Robles-Bolívar P, Parra-Pérez AM, Murillo-Cuesta S, Chua HC, Rodríguez-de la Rosa L, Contreras J, Domarecka E, Amor-Dorado JC, Soto-Varela A, Varela-Nieto I, Szczepek AJ, Gallego-Martínez A, Lopez-Escamez JA. A rare haplotype of the GJD3 gene segregating in familial Meniere's disease interferes with connexin assembly. *Genome Med.* 2025; 17(1): 4. Article. IF: 10.8; D1
- Espejo D, Plaza V, Quirce S, Trigueros JA, Munoz X. Influence of outdoor air pollutants on asthma: a narrative review. *Open Respir Arch.* 2025; 7(3): 100448. Review. Not Indexed
- Farkas H, Anderson J, Bouillet L, Caballero T, Cancian M, Craig T, Fukunaga A, Grivcheva-Panovska V, Guilarte M, Honda D, Kanarek H, Kiani-Alikhan S, Kinaciyan T, Leguevaques D, Longhurst HJ, Magerl M, Manning ME, Martínez-Saguer I, Melamed I, O'Connor ME, Peter J, Savic S, Soteres DF, Staevska M, Staubach P, Stobiecki M, Tachdjian R, Valerieva A, Yong PFK, Hao J, Iverson M,

Smith MD, Yea CM, Audhya PK, Aygören-Pürsün E, Bernstein JA, Cohn DM, Lumry WR, Riedl MA, Zanichelli A, Maurer M. Long-Term Safety and Effectiveness of sebetralstat: Interim analysis of KONFIDENT-S open-label extension. *J Allergy Clin Immunol Pract.* 2025; 13(11): 3094-103. Article. IF: 7.2; D1

- Fokkens WJ, Backer V, Lund VJ, Barnes PJ, Bernal-Sprekelsen M, Bjerrmer L, de Corso E, Conti DM, Cornet ME, Diamant Z, Djukanovic R, Gaga M, Gevaert P, Han JK, Hopkins C, Joos G, Landis BN, Lau S, Lee SE, Mullol J, Peters AT, Scadding GK, Schneider S, Senior B, Pavord ID, Quirce S, Ryan D, Wechsler ME, Hellings PW. Pocket guide: biologics in upper and lower airways in adults. *Rhinology.* 2025; 63(2): 242-4. Letter. IF: 5.7; D1
- González-Barcala FJ, Bobolea I, Domínguez-Ortega J, Bañas-Conejero D, Antelo-Cea E, Martínez-Moragón E, Carrillo-Díaz T, Blanco-Aparicio M, Domingo C. Time is lung: higher preservation of lung function in severe asthma patients after earlier mepolizumab treatment. *ERJ Open Res.* 2025; 11(1): 2112024. Article. IF: 4.4; Q1
- Jesenak M, Bobcakova A, Djukanovic R, Gaga M, Hanania NA, Heaney LG, Pavord I, Quirce S, Ryan D, Fokkens W, Conti D, Hellings PW, Scadding G, Van Staeyen E, Bjerrmer LH, Diamant Z. Promoting prevention and targeting remission of asthma a EUFOREA consensus statement on raising the bar in asthma care. *Chest.* 2025; 167(4): 956-74. Article. IF: 9.8; D1
- Klimek L, Brough HA, Arasi S, Toppila-Salmi S, Bergmann C, Jutel M, Bousquet J, Hox V, Gevaert P, Tomazic PV, Segovia CR, Cingi C, Cuevas M, Gröger M, Huber P, Reitsma S, Rudenko M, Maza-Solano J, Gane S, Karavelia A, van Gerven L, Schiappoli M, Bozkurt B, Becker S, Chaker A, Wollenberg B, Mösges R, Huppertz T, Hagemann J, Palomares O, Bärhold F, Pfaar O, Del Giacco S, Bonadonna P, Moreira A, Agache I, Akdis CA, Fokkens W, Walusiak-Skorupa J, de las Vecillas L, Lozano MA, Giovannini M,

Untersmayr E, Feleszko W, Cianferoni A, Sahiner UM, Eguluz-Gracia I, Shamji M, Jaén MJT. Otitis media with effusion (ome) and eustachian tube dysfunction: the role of allergy and immunity-an eaaci position paper. *Allergy.* 2025; 80(9): 2429-41. Article. IF: 11.3; Q1

- Laorden D, Domínguez-Ortega J, Romero D, Villamañán E, Mariscal-Aguilar P, Granda P, Quirce S, Álvarez-Sala R, ASMAGRAVE HULP Grp. Efficacy assessment of biological treatments in severe asthma. *J Clin Med.* 2025; 14(2): 321. Review. IF: 3.3; Q1
- Longas M, Aponte CS, Laorden D, Romero D, Quirce S, Álvarez-Sala R. Long term effectiveness of mepolizumab in the treatment of chronic eosinophilic pneumonia. *Open Respir Arch.* 2025; 7(3): 100462. Article. Not Indexed
- López-Matas MA, Martín-López L, Vilchez-Sánchez F, Pedrosa M, Rodríguez-Pérez R, Domínguez-Ortega J, Carnés J. Bioinformatics-based prediction of b-and t-cell epitopes in r-mandelonitrile lyase, a recently described peach allergen. *J Invest Allerg Clin.* 2025; 35(3): 220-2. Editorial Material. IF: 6.6; Q1
- López-Matas MA, Vilchez-Sánchez F, Álvarez F, Rodríguez-Pérez R, Domínguez-Ortega J, Carnés J, Pedrosa M. (R)-Mandelonitrile lyase, a homolog of pru du 10, is a major peach allergen. *J Invest Allerg Clin.* 2025; 35(2): 122-9. Article. IF: 6.6; Q1
- Lozano-Espinosa M, Rodríguez-Otero N, Antolín-Amérigo D, Vidal FG, Muriel A, de Pablo R, Quirce S. Characteristics of asthma patients admitted to the intensive care unit of a tertiary university hospital in madrid, spain: a 5-year experience. *J Invest Allerg Clin.* 2025; 35(1): 50-2. Editorial Material. IF: 6.6; Q1
- Martínez-Moragón E, Pinedo C, Puente-Maestu L, Muñoz-Esquerre M, Gómez-Bastero A, Ramos J, Díaz-Palacios M, Hermida T, Bañas-Conejero D, Quirce S. Evaluating the effectiveness and safety of mepolizumab in elderly patients with severe asthma: insights from the REDES study. *J Asthma.* 2025; 62(7): 1128-32. Article. IF: 1.6; Q3
- Martín-González E, Hernández-Pérez JM, Pérez JAP, Pérez-García J, Herrera-Luis E,



1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians



González-Pérez R, González-González O, Mederos-Luís E, Sánchez-Machin I, Poza-Guedes P, Sardón O, Corcuera P, Cruz MJ, González-Barcala EJ, Martínez-Rivera C, Mullol J, Muñoz X, Olaguibel JM, Plaza V, Quirce S, Valero A, Sastre J, Korta-Murua J, del Pozo V, Lorenzo-Díaz F, Villar J, Pino-Yanes M, González-Carracedo MA. Alpha-1 antitrypsin deficiency and Pi*S and Pi*Z SERPINA1 variants are associated with asthma exacerbations. *Pulmonology*. 2025; 31(1): 2416870. Article. IF: 5.3; Q1

• Martín-González E, Pérez-García J, Martín-Almeida M, Hernández-Pérez JM, González-Pérez R, Sardón O, Pérez-Pérez JA, González-Carracedo MA, Poza-Guedes P, Sánchez-Machin I, Mederos-Luís E, Corcuera P, López-Fernández L, Román-Bernal B, González-García LM, Cruz MJ, González-Barcala EJ, Martínez-Rivera C, Mullol J, Muñoz X,

Olaguibel JM, Plaza V, Quirce S, Valero A, Sastre J, del Pozo V, Villar J, Lorenzo-Díaz F, Pino-Yanes M. Genome-wide association study of asthma exacerbations in the spanish population. *Arch Bronconeumol*. 2025; 61(8): 490-4. Letter. IF: 8.7; D1

• Morejón L, Quirce S, Domínguez-Ortega J, Romero D, Nobleja A, Ríos-Blanco J, De Las Vecillas L. Mepolizumab as an effective alternative to immunosuppressive and teratogenic therapies for the early treatment of egpa: a case report. *J Invest Allerg Clin*. 2025; 35(5): 389-91. Editorial Material. IF: 6.6; Q1

• Murillo-Cuesta S, Contreras J, Chioua M, García-Montoya C, Rodríguez-de la Rosa L, Méndez-Grande I, Piotrowska DG, Glowacka IE, Varela-Nieto I, Marco-Contelles J. Quinolyl-nitron 23 protects from auditory cell oxidative injury and noise-induced hearing loss. *ACS Pharmacol Transl Sci*. 2025; 8(9): 3007-18. Article. IF: 4.0; Q2

• Ojanguren I, Quirce S, Bobolea , de Llano LP, del Pozo. Phenotyping asthma exacerbations: one step further in the management of severe asthma. *J Invest Allerg Clin*. 2025; 35(1): 1-11. Review. IF: 6.6; Q1

• Pascal M, Chauhan J, Knol E, Bianchini R, Castells M, de las Vecillas L, Hartmann K, Izquierdo E, Jappe U, Jimenez-Rodriguez TW, Levi-Schaffer F, Mayorga C, Poli A, Redegeld F, Santos AF, Jensen-Jarolim E, Bergmann C, Karagiannis SN, Bax HJ. Basophil activation test: bridging allergy and oncology for diagnostic, therapeutic and prognostic applications in allergooncology: An EAACI position paper. *Allergy*. 2025; 80(8): 2097-112. Article. IF: 11.3; Q1

• Pfaar O, Bilò MB, Csonka P, de Blay F, Gappa M, Gawlik R, Gevaert P, Halken S, Hox V, Kappen J, Krcmová I, Lezmi G, González-Mancebo E, Melen E, Domínguez-Ortega J, Puggioni F, Steinsvåg S, Worm M, Wüstenberg E. Improvement of the therapeutic management of allergic patients in Europe An expert think tank's position paper on allergen immunotherapy. *World Allergy Organ J*. 2025; 18(10): 101109. Article. IF: 4.0; Q2

• Plaza V, Casas-Maldonado F, Cosío BG, García-Rivero JL, González-Pérez R, Moragon EM, Moreno-Ancillo A, Pallares-Sanmartín A, Ramos J, Sánchez S, Domínguez-Ortega J. Severe asthma management in spain: a survey-based national study. Is it time for a national asthma plan?. *Open Respir Arch*. 2025; 7(2): 100408. Article. Not Indexed

• Plaza V, García G, de Llano LP, Quirce S. Initiating biological treatment of asthma: when is the right time? *Arch Bronconeumol*. 2025; 61(1): 3-4. Editorial Material. IF: 8.7; D1

• Pose K, De Las Vecillas L, Tomás-Pérez M, Barranco P, Quirce S, Domínguez-Ortega J. Domestic hypersensitivity pneumonitis caused by inadvertent exposure to feathers. *Rev Allerg Mex*. 2025; 72(4): 276-80. Article. Not Indexed

• Rodríguez-Pérez R, Pulido E, Bellón T, Rodríguez-Álvarez M, Gómez-Traseira C, López-Matas MA, Domínguez-Ortega J, Carnés J, Pedrosa M. FcεRI-bound OVM-slgE

detection: A promising predictor of boiled egg white OFC outcomes. *Pediatr Allerg Imm-Uk*. 2025; 36(7): e70149. Letter. IF: 4.5; Q2

• Santamaria RF, Karavelia A, Giovannini M, de las Vecillas L, Bonadonna P, Del Giacco S, Pfaar O, Skorupa JW, Moreira A, Torres MJ, Shamji M, Palomares O. EAACI clinical and research fellowship program: shaping the future of allergy and clinical immunology. *Allergy*. 2025; 80(6): 1565-8. Editorial Material. IF: 11.3; Q1

• Sousa-Pinto B, de las Vecillas L, Riggioni C, Eigenmann P, Giovannini M. Editorial comment on The effectiveness of an education program based on healthcare transition in adolescents with asthma: A randomized controlled trial. *Pediatr Allerg Imm-Uk*. 2025; 36(10): e70214. Editorial Material. IF: 4.5; Q2

• Sousa-Pinto B, Schleich F, Louis G, Gemicioglu B, Kvedariene V, Regateiro FS, Loureiro CC, Taborda-Barata L, Amaral R, Antó JM, Bedbrook A, Czarlewski W, Ansotegui IJ, Bergmann KC, Bonini M, Bossios A, Boulet LP, Braidó F, Brightling C, Brusselle G, Brussino L, Canonica GW, Cruz AA, Haahtela T, Heaney LG, Hyland M, Ivancevich JC, Klimek L, Kulus M, Kuna P, Kupczyk M, Larenas-Linnemann DE, Makris M, Marqués-Cruz M, Gil-Mata S, Morais-Almeida M, Niedoszytko M, Ollert M, Papadopoulos NG, Patella V, Pfaar O, Porsbjerg C, Puggioni F, Quirce S, Cordeiro CR, Roche N, Samolinski B, Sastre J, Scichilone N, Skrgat S, Toppila-Salmi S, Usmani OS, Valiulis A, Gradauskiene B, Koyuncu IV, Ventura MT, Vieira RJ, Yorgancioglu A, Fonseca JA, Zuberbiel T, Petre B, Louis R, Bousquet J. Daily digital biomarkers in the follow-up and clustering of patients with asthma. *Pulmonology*. 2025; 31(1): 2532980. Article. IF: 5.3; Q1

• Sousa-Pinto B, Vieira RJ, Bognanni A, Martini M, Ordak M, Paoletti G, Gil-Mata S, Amaral R, Bedbrook A, Bonadonna P, Brussino L, Canonica GW, Coutinho-Almeida J, Cruz AA, Czarlewski W, Dykewicz M, Giovannini M, Gemicioglu B, Ivancevich JC, Klimek



1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians

L, Kvedariene V, Larenas-Linnemann DE, Marques-Cruz M, Moreira A, Niedoszytko M, Pereira AM, Papadopoulos NG, Pham-Thi N, Regateiro FS, Toppila-Salmi SK, Samolinski B, Sastre J, Taborda-Barata L, Thomander T, Koyuncu IV, Valiulis A, Vecillas LD, Ventura MT, Walusiak-Skorupa J, Xiang YK, Pfaar O, Fonseca JA, Zuberbier T, Schünemann HJ, di Bona D, Bousquet J. Comparison of allergic rhinitis treatments on patient satisfaction: a MASK-air and EAACI methodological committee report. *Allergy*. 2025; 80(12): 3319-30. Article. IF: 11.3; Q1

• Suojalehto H, Jeebhay MF, Sander I, Quirce S, Vrtala S, Walusiak-Skorupa J, Lopata AL, Vidal C, Raulf M. Occupational mite allergy and asthma: An EAACI task force report. *Allergy*. 2025; 80(9): 2484-500. Review. IF: 11.3; Q1

• Tabar AI, Delgado-Romero J, González-Mancebo E, Domínguez-Ortega J, Soto-Retes L. Safety and effectiveness of allergen immunotherapy in patients with severe allergic asthma. *J Asthma Allergy*. 2025; 18: 1311-26. Article. IF: 3.3; Q2

• Villamañán E, Laorden D, Ibáñez ME, De las Vecillas L, Carpio C, Alfonso C, Domínguez-Ortega J, Romero D, Quirce S, Álvarez-Sala R. Adherence to intranasal corticosteroids in patients with severe asthma and nasal polyposis: pharmacological and clinical factors involved. *J Clin Med*. 2025; 14(14): 5070. Article. IF: 3.3; Q1

• Zuraw BL, Bork K, Bouillet L, Christiansen SC, Farkas H, Germenis AE, Grumach AS, Kaplan A, López-Lera A, Magerl M, Riedl MA, Adatia A, Banerji A, Betschel S, Boccon-Gibod I, Bova M, Boysen HB, Caballero T, Cancian M, Castaldo AJ, Cohn DM, Corcoran D, Drouet C, Fukunaga A, Hide M, Katelaris CH, Li PH, Longhurst H, Peter J, Psarros F, Reshef A, Ritchie B, Selva CN, Zanichelli A, Maurer M. Hereditary angioedema with normal c1 inhibitor: an updated international consensus paper on diagnosis, pathophysiology, and

treatment. *Clin Rev Allerg Immu*. 2025; 68(1): 24. Review. IF: 11.5; D1

Research projects

• Rodríguez Pérez MR; Pedrosa Delgado M. Caracterización alérgica y determinación de la relevancia clínica del polen de encina como alérgeno de interés en pacientes polidráulicos y su relación con el desarrollo de síndrome de alergia oral con alimentos (PI22/00221). ISCIII. 2023-2027. **Management centre:** FIBHULP

• de las Vecillas Sánchez L. Estudio de la inmunomodulación celular inducida en las desensibilizaciones a quimioterápicos tras reacciones alérgicas inmediatas mediadas por IGE y tardías mediadas por linfocitos T específicos (PI24/01046). ISCIII. 2025-2027. **Management centre:** FIBHULP

• Gandolfo Cano M. Exosomas y microRNAs: nuevas herramientas terapéuticas y diagnósticas en la interacción del asma y la alergia alimentaria (PI-6482). 2025-2027. **Management centre:** IIS-Fundación Jiménez Díaz

• Gandolfo Cano M. Estudio del metabolismo microbiano del cacahuete durante inmunoterapia oral (PI-6689). 2025-2027. **Management centre:** Hospital del Niño Jesús

Ciber and Retics

• Caballero Molina MT. Centro de Investigación en Red de Enfermedades Raras. (CIBERer). ISCIII. (31/12/2025). FIBHULP

Clinical trials

• Caballero Molina MT. A phase 3, randomized, double-blind, placebo-controlled, 3-part study to evaluate the efficacy and safety of orally administered deucricitbant xr tablet for prophylaxis and deucricitbant soft capsule for on-demand treatment of angioedema attacks in adults with acquired angioedema due to c1 inhibitor deficiency.

Type/Phase: III

Sponsored by: Pharvaris Netherlands B.V.

Signature date: 02/12/2025

• Domínguez Ortega FJ. T-ROSS II estudio observacional retrospectivo para caracterizar y evaluar los resultados clínicos de pacientes que recibieron tezepelumab después de la autorización de comercialización en España.

Type/Phase: EOm no prospectivo

Sponsored by: Astrazeneca Farmaceutica Spain S.A.

Signature date: 22/05/2025

• Phillips Anglés E. Estudio en fase III para evaluar la seguridad y farmacocinética de la profilaxis con berotralstat en niños de 2 a <12 años con angioedema hereditario.

Type/Phase: III

Sponsored by: Biocryst Pharmaceuticals Inc.

Signature date: 03/09/2025

• Phillips Anglés E. Un estudio abierto para proporcionar acceso a berotralstat a sujetos con angioedema hereditario de tipo 1 y 2 que fueron previamente inscritos en estudios de berotralstat.

Type/Phase: IIb

Sponsored by: Biocryst Pharmaceuticals Inc.

Signature date: 28/10/2025

• Tomás Pérez M. Pragmatic randomized prospective clinical study to evaluate the effectiveness of a digital application to improve aeroallergen immunotherapy adherence in real life. the navigait.me project. Estudio clínico pragmático prospectivo aleatorizado para evaluar la efectividad de una aplicación digital para mejorar la adherencia a inmunoterapia con aeroalérgenos en vida real, proyecto navigait.me.

Type/Phase: OTROS

Sponsored by: Tomás Pérez, Margarita.

Signature date: 17/12/2025

• Torrado Español I. Evaluación de la seguridad y efectividad de beltaven® en pacientes con alergia a apis mellifera, polistes dominula o vespula spp.

Type/Phase: EOm prospectivo

Sponsored by: Probelte Pharma Sa.

Signature date: 23/01/2025

Patents and trademarks

• Valenta R, Constantin C, Quirce Gancedo, SE, inventors; Phadia AB, assignee. Novel wheat allergens. PCT/SE2008/051377, EP2225266, US2010305049, AU2008330230, CA2707190, CN101932597, JP2011505134, RU2010126590; 2007 November 30.

• Caballero Molina MT, Prior Gómez N, Remor Bitencourt EA, authors, FIBHULP, assignee. Brand name: HAE-QoL HEREDITARY ANGIOEDEMA QUALITY OF LIFE. CM 13.083.068; 2014 July 15.

HAE-QoL
HEREDITARY ANGIOEDEMA QUALITY OF LIFE

• Sánchez Herreros R, Martínez Fernández J, Castro Morera A, Gasset Vega M, Rodríguez Pérez RM, Pedrosa Delgado M, Quirce Gancedo S, inventors; FIBHULP, CSIC, assignees. Food allergen extracts and methods of producing and using the same. EP16382413.9 (Publication Number pending); 2016 September 06.

• del Pozo Abejón V, Sastre Dominguez J, Rodrigo-Muñoz JM, Sastre Turrión B, Quirce Gancedo S, Cañas Mañas JA, inventors; FIISJD, Centro de Investigación Biomédica en Red (CIBER), FIBHULP, Fundación Conchita Rábago de Jiménez Díaz, assignees. In vitro method for identifying severity levels in bronchial asthma patients. P201730739; 2017 May 29.

• Villamañán E, Contreras J, Romero D, Carpio C, Álvarez-Sala R, Herrero A, Quirce S, inventors; FIBHULP, assignee. Expertasma. N°018981670; 2024 June 14.

 **expertasma**